Opinion|Videos|July 28, 2026

When Primary OSA Therapy Isn't Enough: Counseling on Residual Sleepiness

Winter opens the discussion by highlighting that millions of Americans with narcolepsy and OSA suffer from undertreated EDS. He sets the stage for understanding the unmet need that solriamfetol addresses.

Megan Maroney, PharmD, BCPP, addresses patients who remain sleepy despite adherence to primary OSA therapies like CPAP, noting that these devices may resolve airway obstruction without fully treating residual EDS. She discusses the point at which lingering sleepiness should prompt a conversation about adding pharmacologic treatment.


Latest CME